Daiichi Sankyo Co. Ltd. Ads (DSNKY) 17.7400 $DSNKY
Daiichi Sankyo Further Expands TaNeDS Collaborative Drug Discovery Program in Europe
PR Newswire Europe - 1 hr 42 mins ago
Daiichi Sankyo Company, Limited announced on September 1 details of the application for its Take a New Challenge for Drug Discovery (TaNeDS) Global Programme 2014, a collaborative drug discovery initiative for universities and research institutes in Europe.
Global Rheumatoid Arthritis Drugs Market 2014-2018
M2 - Mon Jul 28, 6:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tv2rn2/global_rheumatoid) has announced the addition of the "Global Rheumatoid Arthritis Drugs Market 2014-2018" report to their offering. RA is a chronic disease that leads to inflammation and pain in the human body's joints such as wrists, fingers, knees, feet, and ankles. In addition, it causes inflammation of the tissues that surround the joints and in other organs. The symptoms of RA begin slowly, usually just mild pain around the joints coupled with stiffness and fatigue, and in the later stages it causes inflammation of the joints. It can occur at any age, even in children, which is called juvenile arthritis. The disease is three times more common in women than in men. Genetic and environmental elements are known to contribute in the development of RA. The analysts forecast the Global Rheumatoid Arthritis Drugs market will grow at a CAGR of 4.09 percent over the period 2013-2018. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Competitive Assessment of Top Drugs 08. Five Forces Analysis 09. Market Segmentation by Category 10. Geographical Segmentation 11. Buying Criteria 12. Rate of Incidence and Prevalence 13. Pipeline Snapshot 14. Market Growth Drivers 15. Drivers and their Impact 16. Market Challenges 17. Impact of Drivers and Challenges 18. Market Trends 19. Trends and their Impact 20. Vendor Landscape 21. Key Vendor Analysis 22. Other Reports in this Series Companies Mentioned: - AbbVie Inc. - Amgen Inc. - Bristol-Myers Squibb Co. - F. Hoffmann-La Roche Ltd. - Janssen Pharmaceuticals Inc. - Pfizer Inc. - AB Science SA - Astellas Pharma Inc. - AstraZeneca plc - Biogen Idec Inc. - Boehringer Ingelheim GmbH - Celgene Corp. - Daiichi Sankyo Co. Ltd. - Eli Lilly & Co. - GE Healthcare Co. - Genmab A/S - GSK plc - Incyte Corp. - Merck & Co. Inc. - Mitsubishi Tanabe Pharma Corp. - Novartis AG - Novo Nordisk A/S - Rigel Pharmaceuticals Inc. - Sanofi - Takeda Pharmaceutical Co. Ltd. - UCB SA - Vertex Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/tv...rheumatoid
Esophageal Cancer Therapeutic Pipeline Review, H1 2014
M2 - Tue Jul 15, 11:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j6z3g6/esophageal_cancer) has announced the addition of the "Esophageal Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Esophageal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Esophageal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Esophageal Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Esophageal Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Esophageal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Esophageal Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - Amgen Inc. - GlaxoSmithKline plc - Gilead Sciences, Inc. - Daiichi Sankyo Company, Limited - Novartis AG - Ono Pharmaceutical Co., Ltd. - CTI BioPharma Corp. - Genmab A/S - Advaxis, Inc. - Immunomedics, Inc. - Takara Bio Inc. - Synta Pharmaceuticals Corp. - Transgene Biotek Limited - Supratek Pharma Inc. - Glycotope GmbH - Hutchison MediPharma Limited - Advantagene, Inc. - CerRx, Inc. - Cerulean Pharma, Inc. - MacroGenics, Inc. - Merrimack Pharmaceuticals, Inc. - Omnitura Therapeutics Inc. - Omeros Corporation - Oncolys BioPharma Inc. - ImmunoFrontier, Inc. - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Mebiopharm Co., Ltd. - Kite Pharma, Inc For more information visit http://www.researchandmarkets.com/research/j6...eal_cancer
H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2014
M2 - Tue Jul 15, 11:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/748t6b/h5n1_infection) has announced the addition of the "H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for H5N1 Infection (Avian Influenza), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for H5N1 Infection (Avian Influenza) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of H5N1 Infection (Avian Influenza) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for H5N1 Infection (Avian Influenza) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the H5N1 Infection (Avian Influenza) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the H5N1 Infection (Avian Influenza) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Johnson & Johnson - Autoimmune Technologies, LLC - GlaxoSmithKline plc - Inovio Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Emergent BioSolutions Inc. - Generex Biotechnology Corporation - Takeda Pharmaceutical Company Limited - Nanotherapeutics, Inc. - Novartis AG - CEL-SCI Corporation - OPKO Health, Inc. - Hemispherx Biopharma, Inc. - Medicago Inc. - BioDiem Ltd - NanoViricides, Inc. - Medigen Biotechnology Corporation - SIGA Technologies, Inc. - XOMA Corporation - Green Cross Corporation - Antigen Express, Inc. - Adimmune Corporation - TechnoVax, Inc. - Cocrystal Pharma, Inc. - PaxVax - Vivaldi Biosciences Inc. - Aprogen, Inc. - Akshaya Bio Inc. - Gemmus Pharma Inc. For more information visit http://www.researchandmarkets.com/research/74..._infection
Why Portola Pharmaceuticals Inc. Stock Swooned
Sean Williams, The Motley Fool - Motley Fool - Mon Jul 07, 3:29PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Portola Pharmaceuticals , a clinical-stage...
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Review, H1 2014
M2 - Thu Jul 03, 5:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/465jcl/transitional_cell) has announced the addition of the "Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Transitional Cell Carcinoma (Urothelial Cell Carcinoma) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Amgen Inc. - Sanofi - Daiichi Sankyo Company, Limited - Novartis AG - Pfizer Inc. - Teva Pharmaceutical Industries Limited - Dendreon Corporation - Cadila Pharmaceuticals Ltd. For more information visit http://www.researchandmarkets.com/research/46...ional_cell
Global Hypertension Drugs Market 2014-2018
M2 - Thu Jun 26, 10:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tw2n66/global) has announced the addition of the "Global Hypertension Drugs Market 2014-2018" report to their offering. The Global Hypertension Drugs market will grow at a CAGR of 1.2% to 2018 Hypertension, also referred as arterial hypertension or high BP, is a chronic medical condition in which the arterial blood pressure is elevated to an undesired level. Lifestyle habits such as diet, exercising, and smoking are the major causes of hypertension. Hypertension can damage organs and lead to several illnesses such as renal failure, aneurysm, heart failure, stroke, and heart attack. There are two types of hypertension: primary or essential and secondary. The Global Hypertension Drugs market can be categorized into eight segments: - Diuretics - ACE Inhibitors - ARBs - CCB - Beta Blockers - Alpha Blockers - Vasodilators - Renin Inhibitors To calculate the market size, the report considers the revenue generated from the sales of various hypertension drugs used in the treatment of pulmonary arterial hypertension and essential hypertension. The report, the Global Hypertension Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Hypertension Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Vendors - Actelion Ltd. - AstraZeneca plc - Boehringer Ingelheim GmbH - Novartis AG - Pfizer Inc. - Sanofi SA Other Prominent Vendors - Bayer AG - Daiichi Sankyo Co. Ltd. - Forest Laboratories Inc. - Merck & Co. Inc. - Takeda Pharmaceutical Co. Ltd. - United Therapeutics Corp. - Valeant Pharmaceuticals International Inc. - XOMA LLC Key Market Drivers/Challenges/Trends - Increase in Aging Population. - Increasing Number of Patent Expirations. - Increasing Focus on Combination Therapies. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Rate of Incidence and Prevalence - Late Stage Pipeline Snapshot - Market Segmentation by Mechanism of Action - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/tw2n66/global
Pieris Achieves Milestone Payment in Daiichi Sankyo Collaboration to Develop Anticalin(R) Therapeutics
Business Wire - Mon Jun 23, 9:30AM CDT
Pieris AG announced that it has achieved a second milestone for its second program, and fifth milestone overall, in its discovery and development collaboration with Daiichi Sankyo Company Limited (hereinafter Daiichi Sankyo; headquartered in Chuo Ward, Tokyo, TSE 4568), triggering an undisclosed payment. The milestone is based on successful in vitro and in vivo studies validating a range of Anticalin(R) targeted protein drug candidates designed to bind a Daiichi Sankyo target. With this achievement, Pieris will transfer development responsibility of the program to Daiichi Sankyo, who will initiate further in vivo studies in non-human primates.
Pulmonary Embolism - Pipeline Review, H1 2014
M2 - Thu Jun 12, 3:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/263k7j/pulmonary) has announced the addition of the "Pulmonary Embolism - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Pulmonary Embolism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Embolism and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Pulmonary Embolism - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Pulmonary Embolism and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Pulmonary Embolism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Mentioned: - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Daiichi Sankyo Company, Limited - Bayer AG - D-Pharm Ltd. For more information visit http://www.researchandmarkets.com/research/263k7j/pulmonary
Sepsis - Pipeline Review, H1 2014
M2 - Thu Jun 12, 3:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rc2rw6/sepsis_pipeline) has announced the addition of the "Sepsis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Sepsis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sepsis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Sepsis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Sepsis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Sepsis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Mentioned: - Baxter International - Daiichi Sankyo Company - Novo Nordisk - Takeda Pharmaceutical Company - Chiesi Farmaceutici - Chong Kun Dang - Eisai - Huons - MetrioPharm - Opsona Therapeutics - Asahi Kasei - MSM Protein Technologies - VG Life Sciences - OncoImmune - Serum Institute of India - Endacea - ISU ABXIS - KAEL-GemVax - biosyn Arzneimittel - Cognosci - Navigen Pharmaceuticals - Lead Discovery Center - Immune Response BioPharma - Novadiscovery - XImmune - Adrenomed - ImmunNovative Developments - Diomune For more information visit http://www.researchandmarkets.com/research/rc...s_pipeline
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2014
M2 - Thu Jun 12, 2:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7cwmg2/coronary_artery) has announced the addition of the "Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) Companies Mentioned: - Bristol-Myers Squibb Company - AstraZeneca - MedImmune - Isis Pharmaceuticals - Gilead Sciences - Daiichi Sankyo Company - Merck & Co - CardioVascular BioTherapeutics - Bayer AG - AnGes MG - Pluristem Therapeutics - AngioDesign - ViroMed - Miltenyi Biotec - Multi Gene Vascular Systems - Lonestar Heart - Biscayne Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/7c...ary_artery
Global Protein Therapeutics Market 2012-2016: Patent-Expiration of Top-Selling Drugs Could Pose a Challenge to the Growth
M2 - Mon Mar 31, 11:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/x5wp95/global_protein) has announced the addition of the "Global Protein Therapeutics Market 2012-2016" report to their offering. The analysts forecast the Global Protein Therapeutics market to grow at a CAGR of 7.08 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing prevalence of chronic diseases. The market has also been witnessing increasing outsourcing of drug development. The key vendors dominating this space include Roche Holding Ltd., Amgen Inc., Abbott Laboratories, J&J, and Novo Nordisk A/S. The other vendors mentioned in this report are AstraZeneca plc, Biogen Idec Inc., Eli Lilly and Co., Novartis International AG, Bristol Myers Squibb Co., Merck and Co. Inc., Pfizer Inc., Curis Inc., UCB S.A., Elan Corporations Plc, Human Genome Sciences Inc., Daiichi Sankyo Co. Ltd., and GlaxoSmithKline plc. Commenting on the report, an analyst from the Healthcare team said: The development and manufacture of drugs is a complex and time-consuming process, and also requires huge financial investments. As many vendors in the market are facing the problem of declining venture capital investments, they are increasingly following the strategy of outsourcing. Many vendors outsource different parts of the R&D process such as product characterization testing and toxicology testing to CROs. Likewise, a few vendors are increasingly outsourcing a part of their manufacturing process, or the entire manufacturing process to various organizations. Thus, the Global Protein Therapeutics market is currently witnessing the trend of increased outsourcing of drug development activities. For more information visit http://www.researchandmarkets.com/research/x5...al_protein About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Daiichi Sankyo Initiates Phase 3 ENSURE-AF Study, Investigating Once-Daily Edoxaban in Patients with Atrial Fibrillation Undergoing Cardioversion
PR Newswire Europe - Mon Mar 31, 6:01AM CDT
-- First patient enrolled in largest planned phase 3 study evaluating a novel oral anticoagulant in non-valvular atrial fibrillation patients undergoing electrical cardioversion
Global Generic Drugs Market 2014-2018: Branded Drugs with Sales of Up to US$135 Billion to Go Off-Patent by 2015
M2 - Mon Mar 24, 6:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6q8j7g/global_generic) has announced the addition of the "Global Generic Drugs Market 2014-2018" report to their offering. The analysts forecast the Global Generic Drugs market to grow at a CAGR of 11.02 percent over the period 2013-2018. The patent expiry of top-selling drugs is one of the major drivers contributing to the growth of this market. The market is also witnessing an increase in mergers and acquistions. However, intense competition among vendors could squeeze profit margins, increase pricing pressure, and pose a challenge to the growth of this market. Key vendors dominating this space include Actavis plc, Mylan Inc., Novartis International AG (Sandoz), STADA Arzneimittel AG, and Teva Pharmaceutical Industries Ltd. Other vendors mentioned in the report are 3SBio Inc., Amgen Inc., Apotex Inc., AstraZeneca plc, Aurobindo Pharma Ltd., Baxter International Inc., Berlin-Chemie AG, Biocon Ltd., Biogen Idec Inc., Boehringer Ingelheim GmbH, Celltrion Inc., Cipla Ltd., Coherus Biosciences Inc., Daiichi Sankyo Co. Ltd., Dr. Reddy's Laboratories Ltd., Emcure Pharmaceuticals Ltd., Gedeon Richter plc, GlaxoSmithKline plc, Hospira Inc., Impax Laboratories Inc., Intas Pharmaceuticals Ltd., Lupin Ltd., Merck & Co. Inc., Mitsubishi Tanabe Pharma Corp., Par Pharmaceutical Inc., Pfizer Inc., Ranbaxy Laboratories Ltd., Roche Holding AG, Sanofi S.A., Wockhardt Ltd., and Zydus Cadila Healthcare Ltd. Commenting on the report, an analyst from the team said: Mergers and acquisitions has become the core growth strategy among many healthcare vendors; they help vendors grow rapidly and expand their businesses. The Global Generic Drugs market has witnessed a number of mergers and acquisitions among the leading vendors. Vendors have been primarily focusing on mergers and acquisitions to increase their scale, revenue, market share, and competitive advantage. For instance, in November 2012, Actavis acquired Watson Pharmaceuticals and became the third largest generic pharmaceutical company across the globe, with operations in more than 60 countries. In October 2013, Actavis acquired Warner Chilcott plc for approximately US$8.5 billion. Moreover, in 2011, Teva acquired Ratiopharm AG, a leading generic drug manufacturer in Europe, to maintain its position in the market. For more information visit http://www.researchandmarkets.com/research/6q...al_generic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Once-Daily Edoxaban Evaluated in Two Subgroup Analyses of East Asian Patients from the Largest Comparative Phase 3 Trials of a Novel Oral Anticoagulant
PR Newswire - Mon Mar 24, 6:00AM CDT
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced late-breaking data from two pre-specified subgroup analyses of East Asian patients with non-valvular atrial fibrillation (NVAF) or venous thromboembolism (VTE) enrolled in two phase 3 edoxaban studies. The findings of the two subgroup analyses of 1,943 East Asian patients (Japan, China, Korea and Taiwan) enrolled in the ENGAGE AF-TIMI 48 study and 1,101 East Asian patients enrolled in the Hokusai-VTE study were consistent with the results from the global study populations, which demonstrated investigational edoxaban was comparable to warfarin for the prevention of stroke or systemic embolic events (SEE) in NVAF patients and for the treatment and prevention of VTE, respectively. The subgroup analyses also demonstrated findings consistent with the full study populations for the principal safety outcomes in both studies. The data were presented at the Japanese Circulation Society 2014 Annual Scientific Meeting in Tokyo, Japan.1,2,3,4
Global Biosimilars Market 2014-2018: Patent Expirations and More
M2 - Wed Mar 05, 11:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/jggmhc/global) has announced the addition of the "Global Biosimilars Market 2014-2018" report to their offering. The analysts forecast the Global Biosimilars Market to grow at a CAGR of 27.58 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing number of patent expirations. The Global Biosimilars Market has also been witnessing the outsourcing of biosimilar manufacturing. However, the risks related to drug failure could pose a challenge to the growth of this market. Key vendors dominating this space include Biocon Ltd., Hospira Inc., Mylan Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., Dr. Reddy's Laboratories Ltd., F. Hoffmann-La Roche Ltd., 3SBio Inc., and Celltrion Inc. Other vendors mentioned in the report are Actavis plc, Amgen Inc., AstraZeneca plc, Baxter International Inc., Biogen Idec Inc., Bioton S.A., Boehringer Ingelheim GmbH, Cipla Ltd., Coherus Biosciences Inc., Daiichi Sankyo Co. Ltd., Emcure Pharmaceuticals Ltd., GE Healthcare Ltd., GeneScience Pharmaceuticals Co. Ltd., GlaxoSmithKline plc, JCR Pharmaceuticals Co. Ltd., iBio Inc., LG Life Sciences Co. Ltd., Merck & Co. Inc., Pfizer Inc., Ranbaxy Laboratories Ltd., Samsung Biologics Co. Ltd., Sanofi S.A., and Wockhardt Ltd. Commenting on the report, an analyst from the team said: The manufacture of biosimilar products requires specialized capabilities, meticulous planning, highly skilled staff, and significant financial investment in equipment, technology, materials, and personnel. Therefore, the complexities and costs involved in the biosimilar development rises along with the dip in their profit margins, hampering the overall success of manufacturing biosimilar products. Thus, many vendors are increasingly turning to CMOs and CROs that have already gained proficiency in the field of manufacturing biosimilar products. The wealth of knowledge, experience, understanding, technology, skills and financial control that CMOs and CROs can provide to manufacturers, make this a solution that many vendors are using at present. These organizations employ well-trained professionals to develop and validate analytical methods, providing pharmaceutical companies with a feasible way of remaining competitive and financially viable. This new trend is expected to have a positive impact on the growth of the market over the next few years. For more information visit http://www.researchandmarkets.com/research/jggmhc/global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Concise Analysis of the Future Prospects of Global Personalized Medicine Market
M2 - Tue Mar 04, 5:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/zpctsr/future_prospects) has announced the addition of the "Concise Analysis of the Future Prospects of Global Personalized Medicine Market" report to their offering. Over the years, the Global Personalized Medicine market has been witnessing the emergence of various tools and technologies from the reputed vendors. For instance, AssureRx Health Inc. launched GeneSightRx ADHD in May 2012, a personalized medicine test for the growing number of children and adults diagnosed with ADHD. Moreover, Bristol-Myers Squibb Co. collaborated with MMRF in December 2012 for advanced personalized medicine for multiple Myeloma. Further, Alacris Theranostics GmbH entered into an agreement with GlaxoSmithKline plc in November 2012 to use ModCell system for early stage cancer research. Further, AltheaDx Inc. launched FLT3 Mutation Assay in October 2012. Agendia N.V. launched ColoPrint microarray-based 18-gene expression signature in June 2012 for predicting the risk of distant recurrence for stage II colon cancer patients. The European Medicines Agency approved Zelboraf, manufactured by F. Hoffmann-La Roche Ltd., in December 2011. Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Geographical Segmentation 8. Key Leading Countries 9. Vendor Landscape 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Key Vendor Analysis 17. Other Reports in this Series Companies Mentioned: - Abbott Laboratories - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Co. - Celgene Corp. - Daiichi Sankyo Co. Ltd. - Danaher Corp. - Eli Lilly and Co. - Evotec AG - F. Hoffmann-La Roche Ltd. - GE Healthcare Ltd. - Genelex Corp. - GlaxoSmithKline plc - Hologic Inc. - Johnson & Johnson - Laboratory Corporation of America Holdings - Life Technologies Corp. - Merck KGaA - Mitsubishi Tanabe Pharma Corp. - Myriad Genetics Inc. - Novartis AG - Novartis AG - PerkinElmer Inc. - Pfizer Inc. - Pfizer Inc. - Quest Diagnostics Inc. - Sanofi S.A. - Sanofi S.A. - Siemens Healthcare - Sigma-Aldrich Corp. - Takeda Pharmaceutical Co. Ltd. - Teva Pharmaceutical Industries Ltd. - Thermo Fisher Scientific Inc. - Transgenomic Inc. For more information visit http://www.researchandmarkets.com/research/zp..._prospects
Daiichi Sankyo Further Expands TaNeDS Collaborative Drug Discovery Program in Europe
PR Newswire Europe - 1 hr 42 mins ago
Daiichi Sankyo Company, Limited announced on September 1 details of the application for its Take a New Challenge for Drug Discovery (TaNeDS) Global Programme 2014, a collaborative drug discovery initiative for universities and research institutes in Europe.
Global Rheumatoid Arthritis Drugs Market 2014-2018
M2 - Mon Jul 28, 6:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tv2rn2/global_rheumatoid) has announced the addition of the "Global Rheumatoid Arthritis Drugs Market 2014-2018" report to their offering. RA is a chronic disease that leads to inflammation and pain in the human body's joints such as wrists, fingers, knees, feet, and ankles. In addition, it causes inflammation of the tissues that surround the joints and in other organs. The symptoms of RA begin slowly, usually just mild pain around the joints coupled with stiffness and fatigue, and in the later stages it causes inflammation of the joints. It can occur at any age, even in children, which is called juvenile arthritis. The disease is three times more common in women than in men. Genetic and environmental elements are known to contribute in the development of RA. The analysts forecast the Global Rheumatoid Arthritis Drugs market will grow at a CAGR of 4.09 percent over the period 2013-2018. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Competitive Assessment of Top Drugs 08. Five Forces Analysis 09. Market Segmentation by Category 10. Geographical Segmentation 11. Buying Criteria 12. Rate of Incidence and Prevalence 13. Pipeline Snapshot 14. Market Growth Drivers 15. Drivers and their Impact 16. Market Challenges 17. Impact of Drivers and Challenges 18. Market Trends 19. Trends and their Impact 20. Vendor Landscape 21. Key Vendor Analysis 22. Other Reports in this Series Companies Mentioned: - AbbVie Inc. - Amgen Inc. - Bristol-Myers Squibb Co. - F. Hoffmann-La Roche Ltd. - Janssen Pharmaceuticals Inc. - Pfizer Inc. - AB Science SA - Astellas Pharma Inc. - AstraZeneca plc - Biogen Idec Inc. - Boehringer Ingelheim GmbH - Celgene Corp. - Daiichi Sankyo Co. Ltd. - Eli Lilly & Co. - GE Healthcare Co. - Genmab A/S - GSK plc - Incyte Corp. - Merck & Co. Inc. - Mitsubishi Tanabe Pharma Corp. - Novartis AG - Novo Nordisk A/S - Rigel Pharmaceuticals Inc. - Sanofi - Takeda Pharmaceutical Co. Ltd. - UCB SA - Vertex Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/tv...rheumatoid
Esophageal Cancer Therapeutic Pipeline Review, H1 2014
M2 - Tue Jul 15, 11:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j6z3g6/esophageal_cancer) has announced the addition of the "Esophageal Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Esophageal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Esophageal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Esophageal Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Esophageal Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Esophageal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Esophageal Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - Amgen Inc. - GlaxoSmithKline plc - Gilead Sciences, Inc. - Daiichi Sankyo Company, Limited - Novartis AG - Ono Pharmaceutical Co., Ltd. - CTI BioPharma Corp. - Genmab A/S - Advaxis, Inc. - Immunomedics, Inc. - Takara Bio Inc. - Synta Pharmaceuticals Corp. - Transgene Biotek Limited - Supratek Pharma Inc. - Glycotope GmbH - Hutchison MediPharma Limited - Advantagene, Inc. - CerRx, Inc. - Cerulean Pharma, Inc. - MacroGenics, Inc. - Merrimack Pharmaceuticals, Inc. - Omnitura Therapeutics Inc. - Omeros Corporation - Oncolys BioPharma Inc. - ImmunoFrontier, Inc. - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Mebiopharm Co., Ltd. - Kite Pharma, Inc For more information visit http://www.researchandmarkets.com/research/j6...eal_cancer
H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2014
M2 - Tue Jul 15, 11:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/748t6b/h5n1_infection) has announced the addition of the "H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for H5N1 Infection (Avian Influenza), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for H5N1 Infection (Avian Influenza) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of H5N1 Infection (Avian Influenza) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for H5N1 Infection (Avian Influenza) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the H5N1 Infection (Avian Influenza) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the H5N1 Infection (Avian Influenza) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Johnson & Johnson - Autoimmune Technologies, LLC - GlaxoSmithKline plc - Inovio Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Emergent BioSolutions Inc. - Generex Biotechnology Corporation - Takeda Pharmaceutical Company Limited - Nanotherapeutics, Inc. - Novartis AG - CEL-SCI Corporation - OPKO Health, Inc. - Hemispherx Biopharma, Inc. - Medicago Inc. - BioDiem Ltd - NanoViricides, Inc. - Medigen Biotechnology Corporation - SIGA Technologies, Inc. - XOMA Corporation - Green Cross Corporation - Antigen Express, Inc. - Adimmune Corporation - TechnoVax, Inc. - Cocrystal Pharma, Inc. - PaxVax - Vivaldi Biosciences Inc. - Aprogen, Inc. - Akshaya Bio Inc. - Gemmus Pharma Inc. For more information visit http://www.researchandmarkets.com/research/74..._infection
Why Portola Pharmaceuticals Inc. Stock Swooned
Sean Williams, The Motley Fool - Motley Fool - Mon Jul 07, 3:29PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Portola Pharmaceuticals , a clinical-stage...
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Review, H1 2014
M2 - Thu Jul 03, 5:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/465jcl/transitional_cell) has announced the addition of the "Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Transitional Cell Carcinoma (Urothelial Cell Carcinoma) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Amgen Inc. - Sanofi - Daiichi Sankyo Company, Limited - Novartis AG - Pfizer Inc. - Teva Pharmaceutical Industries Limited - Dendreon Corporation - Cadila Pharmaceuticals Ltd. For more information visit http://www.researchandmarkets.com/research/46...ional_cell
Global Hypertension Drugs Market 2014-2018
M2 - Thu Jun 26, 10:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tw2n66/global) has announced the addition of the "Global Hypertension Drugs Market 2014-2018" report to their offering. The Global Hypertension Drugs market will grow at a CAGR of 1.2% to 2018 Hypertension, also referred as arterial hypertension or high BP, is a chronic medical condition in which the arterial blood pressure is elevated to an undesired level. Lifestyle habits such as diet, exercising, and smoking are the major causes of hypertension. Hypertension can damage organs and lead to several illnesses such as renal failure, aneurysm, heart failure, stroke, and heart attack. There are two types of hypertension: primary or essential and secondary. The Global Hypertension Drugs market can be categorized into eight segments: - Diuretics - ACE Inhibitors - ARBs - CCB - Beta Blockers - Alpha Blockers - Vasodilators - Renin Inhibitors To calculate the market size, the report considers the revenue generated from the sales of various hypertension drugs used in the treatment of pulmonary arterial hypertension and essential hypertension. The report, the Global Hypertension Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Hypertension Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Vendors - Actelion Ltd. - AstraZeneca plc - Boehringer Ingelheim GmbH - Novartis AG - Pfizer Inc. - Sanofi SA Other Prominent Vendors - Bayer AG - Daiichi Sankyo Co. Ltd. - Forest Laboratories Inc. - Merck & Co. Inc. - Takeda Pharmaceutical Co. Ltd. - United Therapeutics Corp. - Valeant Pharmaceuticals International Inc. - XOMA LLC Key Market Drivers/Challenges/Trends - Increase in Aging Population. - Increasing Number of Patent Expirations. - Increasing Focus on Combination Therapies. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Rate of Incidence and Prevalence - Late Stage Pipeline Snapshot - Market Segmentation by Mechanism of Action - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/tw2n66/global
Pieris Achieves Milestone Payment in Daiichi Sankyo Collaboration to Develop Anticalin(R) Therapeutics
Business Wire - Mon Jun 23, 9:30AM CDT
Pieris AG announced that it has achieved a second milestone for its second program, and fifth milestone overall, in its discovery and development collaboration with Daiichi Sankyo Company Limited (hereinafter Daiichi Sankyo; headquartered in Chuo Ward, Tokyo, TSE 4568), triggering an undisclosed payment. The milestone is based on successful in vitro and in vivo studies validating a range of Anticalin(R) targeted protein drug candidates designed to bind a Daiichi Sankyo target. With this achievement, Pieris will transfer development responsibility of the program to Daiichi Sankyo, who will initiate further in vivo studies in non-human primates.
Pulmonary Embolism - Pipeline Review, H1 2014
M2 - Thu Jun 12, 3:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/263k7j/pulmonary) has announced the addition of the "Pulmonary Embolism - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Pulmonary Embolism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Embolism and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Pulmonary Embolism - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Pulmonary Embolism and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Pulmonary Embolism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Mentioned: - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Daiichi Sankyo Company, Limited - Bayer AG - D-Pharm Ltd. For more information visit http://www.researchandmarkets.com/research/263k7j/pulmonary
Sepsis - Pipeline Review, H1 2014
M2 - Thu Jun 12, 3:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rc2rw6/sepsis_pipeline) has announced the addition of the "Sepsis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Sepsis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sepsis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Sepsis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Sepsis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Sepsis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Mentioned: - Baxter International - Daiichi Sankyo Company - Novo Nordisk - Takeda Pharmaceutical Company - Chiesi Farmaceutici - Chong Kun Dang - Eisai - Huons - MetrioPharm - Opsona Therapeutics - Asahi Kasei - MSM Protein Technologies - VG Life Sciences - OncoImmune - Serum Institute of India - Endacea - ISU ABXIS - KAEL-GemVax - biosyn Arzneimittel - Cognosci - Navigen Pharmaceuticals - Lead Discovery Center - Immune Response BioPharma - Novadiscovery - XImmune - Adrenomed - ImmunNovative Developments - Diomune For more information visit http://www.researchandmarkets.com/research/rc...s_pipeline
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2014
M2 - Thu Jun 12, 2:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7cwmg2/coronary_artery) has announced the addition of the "Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) Companies Mentioned: - Bristol-Myers Squibb Company - AstraZeneca - MedImmune - Isis Pharmaceuticals - Gilead Sciences - Daiichi Sankyo Company - Merck & Co - CardioVascular BioTherapeutics - Bayer AG - AnGes MG - Pluristem Therapeutics - AngioDesign - ViroMed - Miltenyi Biotec - Multi Gene Vascular Systems - Lonestar Heart - Biscayne Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/7c...ary_artery
Global Protein Therapeutics Market 2012-2016: Patent-Expiration of Top-Selling Drugs Could Pose a Challenge to the Growth
M2 - Mon Mar 31, 11:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/x5wp95/global_protein) has announced the addition of the "Global Protein Therapeutics Market 2012-2016" report to their offering. The analysts forecast the Global Protein Therapeutics market to grow at a CAGR of 7.08 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing prevalence of chronic diseases. The market has also been witnessing increasing outsourcing of drug development. The key vendors dominating this space include Roche Holding Ltd., Amgen Inc., Abbott Laboratories, J&J, and Novo Nordisk A/S. The other vendors mentioned in this report are AstraZeneca plc, Biogen Idec Inc., Eli Lilly and Co., Novartis International AG, Bristol Myers Squibb Co., Merck and Co. Inc., Pfizer Inc., Curis Inc., UCB S.A., Elan Corporations Plc, Human Genome Sciences Inc., Daiichi Sankyo Co. Ltd., and GlaxoSmithKline plc. Commenting on the report, an analyst from the Healthcare team said: The development and manufacture of drugs is a complex and time-consuming process, and also requires huge financial investments. As many vendors in the market are facing the problem of declining venture capital investments, they are increasingly following the strategy of outsourcing. Many vendors outsource different parts of the R&D process such as product characterization testing and toxicology testing to CROs. Likewise, a few vendors are increasingly outsourcing a part of their manufacturing process, or the entire manufacturing process to various organizations. Thus, the Global Protein Therapeutics market is currently witnessing the trend of increased outsourcing of drug development activities. For more information visit http://www.researchandmarkets.com/research/x5...al_protein About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Daiichi Sankyo Initiates Phase 3 ENSURE-AF Study, Investigating Once-Daily Edoxaban in Patients with Atrial Fibrillation Undergoing Cardioversion
PR Newswire Europe - Mon Mar 31, 6:01AM CDT
-- First patient enrolled in largest planned phase 3 study evaluating a novel oral anticoagulant in non-valvular atrial fibrillation patients undergoing electrical cardioversion
Global Generic Drugs Market 2014-2018: Branded Drugs with Sales of Up to US$135 Billion to Go Off-Patent by 2015
M2 - Mon Mar 24, 6:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6q8j7g/global_generic) has announced the addition of the "Global Generic Drugs Market 2014-2018" report to their offering. The analysts forecast the Global Generic Drugs market to grow at a CAGR of 11.02 percent over the period 2013-2018. The patent expiry of top-selling drugs is one of the major drivers contributing to the growth of this market. The market is also witnessing an increase in mergers and acquistions. However, intense competition among vendors could squeeze profit margins, increase pricing pressure, and pose a challenge to the growth of this market. Key vendors dominating this space include Actavis plc, Mylan Inc., Novartis International AG (Sandoz), STADA Arzneimittel AG, and Teva Pharmaceutical Industries Ltd. Other vendors mentioned in the report are 3SBio Inc., Amgen Inc., Apotex Inc., AstraZeneca plc, Aurobindo Pharma Ltd., Baxter International Inc., Berlin-Chemie AG, Biocon Ltd., Biogen Idec Inc., Boehringer Ingelheim GmbH, Celltrion Inc., Cipla Ltd., Coherus Biosciences Inc., Daiichi Sankyo Co. Ltd., Dr. Reddy's Laboratories Ltd., Emcure Pharmaceuticals Ltd., Gedeon Richter plc, GlaxoSmithKline plc, Hospira Inc., Impax Laboratories Inc., Intas Pharmaceuticals Ltd., Lupin Ltd., Merck & Co. Inc., Mitsubishi Tanabe Pharma Corp., Par Pharmaceutical Inc., Pfizer Inc., Ranbaxy Laboratories Ltd., Roche Holding AG, Sanofi S.A., Wockhardt Ltd., and Zydus Cadila Healthcare Ltd. Commenting on the report, an analyst from the team said: Mergers and acquisitions has become the core growth strategy among many healthcare vendors; they help vendors grow rapidly and expand their businesses. The Global Generic Drugs market has witnessed a number of mergers and acquisitions among the leading vendors. Vendors have been primarily focusing on mergers and acquisitions to increase their scale, revenue, market share, and competitive advantage. For instance, in November 2012, Actavis acquired Watson Pharmaceuticals and became the third largest generic pharmaceutical company across the globe, with operations in more than 60 countries. In October 2013, Actavis acquired Warner Chilcott plc for approximately US$8.5 billion. Moreover, in 2011, Teva acquired Ratiopharm AG, a leading generic drug manufacturer in Europe, to maintain its position in the market. For more information visit http://www.researchandmarkets.com/research/6q...al_generic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Once-Daily Edoxaban Evaluated in Two Subgroup Analyses of East Asian Patients from the Largest Comparative Phase 3 Trials of a Novel Oral Anticoagulant
PR Newswire - Mon Mar 24, 6:00AM CDT
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced late-breaking data from two pre-specified subgroup analyses of East Asian patients with non-valvular atrial fibrillation (NVAF) or venous thromboembolism (VTE) enrolled in two phase 3 edoxaban studies. The findings of the two subgroup analyses of 1,943 East Asian patients (Japan, China, Korea and Taiwan) enrolled in the ENGAGE AF-TIMI 48 study and 1,101 East Asian patients enrolled in the Hokusai-VTE study were consistent with the results from the global study populations, which demonstrated investigational edoxaban was comparable to warfarin for the prevention of stroke or systemic embolic events (SEE) in NVAF patients and for the treatment and prevention of VTE, respectively. The subgroup analyses also demonstrated findings consistent with the full study populations for the principal safety outcomes in both studies. The data were presented at the Japanese Circulation Society 2014 Annual Scientific Meeting in Tokyo, Japan.1,2,3,4
Global Biosimilars Market 2014-2018: Patent Expirations and More
M2 - Wed Mar 05, 11:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/jggmhc/global) has announced the addition of the "Global Biosimilars Market 2014-2018" report to their offering. The analysts forecast the Global Biosimilars Market to grow at a CAGR of 27.58 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing number of patent expirations. The Global Biosimilars Market has also been witnessing the outsourcing of biosimilar manufacturing. However, the risks related to drug failure could pose a challenge to the growth of this market. Key vendors dominating this space include Biocon Ltd., Hospira Inc., Mylan Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., Dr. Reddy's Laboratories Ltd., F. Hoffmann-La Roche Ltd., 3SBio Inc., and Celltrion Inc. Other vendors mentioned in the report are Actavis plc, Amgen Inc., AstraZeneca plc, Baxter International Inc., Biogen Idec Inc., Bioton S.A., Boehringer Ingelheim GmbH, Cipla Ltd., Coherus Biosciences Inc., Daiichi Sankyo Co. Ltd., Emcure Pharmaceuticals Ltd., GE Healthcare Ltd., GeneScience Pharmaceuticals Co. Ltd., GlaxoSmithKline plc, JCR Pharmaceuticals Co. Ltd., iBio Inc., LG Life Sciences Co. Ltd., Merck & Co. Inc., Pfizer Inc., Ranbaxy Laboratories Ltd., Samsung Biologics Co. Ltd., Sanofi S.A., and Wockhardt Ltd. Commenting on the report, an analyst from the team said: The manufacture of biosimilar products requires specialized capabilities, meticulous planning, highly skilled staff, and significant financial investment in equipment, technology, materials, and personnel. Therefore, the complexities and costs involved in the biosimilar development rises along with the dip in their profit margins, hampering the overall success of manufacturing biosimilar products. Thus, many vendors are increasingly turning to CMOs and CROs that have already gained proficiency in the field of manufacturing biosimilar products. The wealth of knowledge, experience, understanding, technology, skills and financial control that CMOs and CROs can provide to manufacturers, make this a solution that many vendors are using at present. These organizations employ well-trained professionals to develop and validate analytical methods, providing pharmaceutical companies with a feasible way of remaining competitive and financially viable. This new trend is expected to have a positive impact on the growth of the market over the next few years. For more information visit http://www.researchandmarkets.com/research/jggmhc/global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Concise Analysis of the Future Prospects of Global Personalized Medicine Market
M2 - Tue Mar 04, 5:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/zpctsr/future_prospects) has announced the addition of the "Concise Analysis of the Future Prospects of Global Personalized Medicine Market" report to their offering. Over the years, the Global Personalized Medicine market has been witnessing the emergence of various tools and technologies from the reputed vendors. For instance, AssureRx Health Inc. launched GeneSightRx ADHD in May 2012, a personalized medicine test for the growing number of children and adults diagnosed with ADHD. Moreover, Bristol-Myers Squibb Co. collaborated with MMRF in December 2012 for advanced personalized medicine for multiple Myeloma. Further, Alacris Theranostics GmbH entered into an agreement with GlaxoSmithKline plc in November 2012 to use ModCell system for early stage cancer research. Further, AltheaDx Inc. launched FLT3 Mutation Assay in October 2012. Agendia N.V. launched ColoPrint microarray-based 18-gene expression signature in June 2012 for predicting the risk of distant recurrence for stage II colon cancer patients. The European Medicines Agency approved Zelboraf, manufactured by F. Hoffmann-La Roche Ltd., in December 2011. Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Geographical Segmentation 8. Key Leading Countries 9. Vendor Landscape 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Key Vendor Analysis 17. Other Reports in this Series Companies Mentioned: - Abbott Laboratories - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Co. - Celgene Corp. - Daiichi Sankyo Co. Ltd. - Danaher Corp. - Eli Lilly and Co. - Evotec AG - F. Hoffmann-La Roche Ltd. - GE Healthcare Ltd. - Genelex Corp. - GlaxoSmithKline plc - Hologic Inc. - Johnson & Johnson - Laboratory Corporation of America Holdings - Life Technologies Corp. - Merck KGaA - Mitsubishi Tanabe Pharma Corp. - Myriad Genetics Inc. - Novartis AG - Novartis AG - PerkinElmer Inc. - Pfizer Inc. - Pfizer Inc. - Quest Diagnostics Inc. - Sanofi S.A. - Sanofi S.A. - Siemens Healthcare - Sigma-Aldrich Corp. - Takeda Pharmaceutical Co. Ltd. - Teva Pharmaceutical Industries Ltd. - Thermo Fisher Scientific Inc. - Transgenomic Inc. For more information visit http://www.researchandmarkets.com/research/zp..._prospects
